The Effect of Aspirin on Recurrent Fetal Loss in Experimental Antiphospholipid Syndrome
Article first published online: 9 MAY 2013
American Journal of Reproductive Immunology
Volume 29, Issue 3, pages 155–161, April 1993
How to Cite
KRAUSE, I., BLANK, M., GILBRUT, B. and SHOENFELD, Y. (1993), The Effect of Aspirin on Recurrent Fetal Loss in Experimental Antiphospholipid Syndrome. American Journal of Reproductive Immunology, 29: 155–161. doi: 10.1111/j.1600-0897.1993.tb00581.x
- Issue published online: 9 MAY 2013
- Article first published online: 9 MAY 2013
- Accepted January 21, 1993
- Anticardiolipin antibodies;
- antiphospholipid syndrome;
- fetal loss;
PURPOSE: To evaluate the effect of aspirin treatment upon fetal loss in mice with experimental antiphospholipid syndrome (APLS).
MATERIALS AND METHODS: Experimental APLS was induced in pregnant mice by passive transfer of mouse monoclonal anticardiolipin antibody. The mice were treated with high (100μg/d) or low (10μg/d) does of aspirin, using vitaminC(100μg/d or 10μg/d)as a control. The mice were assessed for the presence of lupus anticoagulants (prolonged aPTT), thrombocytopenia, degree of fetal resorption rate and mean embryo and placental weights.
RESULTS: The mice with APLS had a higher fetal resorption rate(45.7± 12.2% vs 2.5 ± 0.4%, P<0.001), reduced placenta mean weight(104 ± 8 mgvs 169 ±7mg, P<0.001), prolonged aPTT (94± 14sec vs 39±4sec, P<0.001), and reduced mean platelet count(597± 186 ± 103/mm3vs 847±51 ± 103/mm3,P<0.001). The groupof mice with APLS, who were treated with low-dose aspirin, had a lower resorption rate (11.1 ±9.3% vs 45.7±12.2%, P<0.001), a higher placenta mean weight (178 ± 8 mg vs 104 ± 8 mg, P<0.001), a higher mean embryo weight (1042 ± 134 mg vs 721±91 mg, P<0.001), and a lower aPTT (58±15 sec vs 94±14 sec, P, <0.001). Micewho were treated with high-dose aspirin also had a lower resorption rate, although not as much as in the low-dose aspirin group (34.2 ± 12.7% vs 45.7 ± 12.2%, P<0.001).
CONCLUSION: Aspirin, especially in low dose, has a protective effect against obstetrical complications associated with experimental APLS.